Economic Burden of Obesity in Italy

Background/Objectives: Quantify the economic burden of obesity in Italy and explore, through an illustrative scenario-based approach, the potential budgetary implications for the Italian National Health Service (NHS) of full reimbursement of modern Obesity Management Medications (OMMs), including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. Methods: Narrative review based on literature searches of PubMed/MEDLINE, Scopus, and Google Scholar from inception to September 2026 and covering the epidemiology and economic burden of obesity in Italy, the current AIFA reimbursement landscape, cost-effectiveness evidence for approved OMMs, and international reimbursement models. Evidence synthesized from cost-of-illness studies, clinical trials, health technology assessments, and economic modeling. Results: Obesity imposes an estimated €13 billion annual burden on Italy (direct costs €7.89 billion; indirect costs €5.45 billion). AIFA currently restricts reimbursement primarily to patients with obesity plus type 2 diabetes mellitus (T2DM) via Nota 13, excluding the majority of individuals with obesity. Modern pharmacotherapies, including semaglutide 2.4 mg and tirzepatide, achieve 12–22% weight reduction with favorable cost-effectiveness ratios in several non-Italian economic evaluations, whereas Italian-specific analyses are lacking. In an illustrative scenario-based estimate derived from indirect modelling assumptions (not a validated decision-analytic, budget-impact, or cost-effectiveness model, and without formal sensitivity analysis), full reimbursement could avoid approximately €2–4 billion in obesity-related healthcare costs over 10 years (gross avoided costs; medication expenditure was not netted off and net savings were not demonstrated) through prevention of T2DM, cardiovascular disease (CVD), obstructive sleep apnea (OSA), and other obesity-related comorbidities. Conclusions: Full reimbursement of evidence-based Obesity Management Medications (OMMs) may offer long-term value for the Italian NHS, although reimbursement decisions require dedicated Italian cost-effectiveness and budget-impact analyses. Policy priorities should include expanding AIFA Nota 13 criteria, implementing outcomes-based risk-sharing agreements, and formally recognizing obesity as a chronic disease in Italian health policy.

Authors

Institutions

Publication Details

Journal
Healthcare
Published
2026-11-17
DOI
https://doi.org/10.3390/healthcare14223942
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Economic Burden of Obesity in Italy

Aldo Eugenio Calogero, Sandro La Vignera
3 links
Healthcare
Pharmacology and Obesity Treatment
article

Economic Burden of Obesity in Italy

Aldo Eugenio Calogero, Sandro La Vignera
article en

Abstract

Background/Objectives: Quantify the economic burden of obesity in Italy and explore, through an illustrative scenario-based approach, the potential budgetary implications for the Italian National Health Service (NHS) of full reimbursement of modern Obesity Management Medications (OMMs), including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. Methods: Narrative review based on literature searches of PubMed/MEDLINE, Scopus, and Google Scholar from inception to September 2026 and covering the epidemiology and economic burden of obesity in Italy, the current AIFA reimbursement landscape, cost-effectiveness evidence for approved OMMs, and international reimbursement models. Evidence synthesized from cost-of-illness studies, clinical trials, health technology assessments, and economic modeling. Results: Obesity imposes an estimated €13 billion annual burden on Italy (direct costs €7.89 billion; indirect costs €5.45 billion). AIFA currently restricts reimbursement primarily to patients with obesity plus type 2 diabetes mellitus (T2DM) via Nota 13, excluding the majority of individuals with obesity. Modern pharmacotherapies, including semaglutide 2.4 mg and tirzepatide, achieve 12–22% weight reduction with favorable cost-effectiveness ratios in several non-Italian economic evaluations, whereas Italian-specific analyses are lacking. In an illustrative scenario-based estimate derived from indirect modelling assumptions (not a validated decision-analytic, budget-impact, or cost-effectiveness model, and without formal sensitivity analysis), full reimbursement could avoid approximately €2–4 billion in obesity-related healthcare costs over 10 years (gross avoided costs; medication expenditure was not netted off and net savings were not demonstrated) through prevention of T2DM, cardiovascular disease (CVD), obstructive sleep apnea (OSA), and other obesity-related comorbidities. Conclusions: Full reimbursement of evidence-based Obesity Management Medications (OMMs) may offer long-term value for the Italian NHS, although reimbursement decisions require dedicated Italian cost-effectiveness and budget-impact analyses. Policy priorities should include expanding AIFA Nota 13 criteria, implementing outcomes-based risk-sharing agreements, and formally recognizing obesity as a chronic disease in Italian health policy.

HealthcareVol. 14(22)
University of Catania (IT)
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon